160 related articles for article (PubMed ID: 21845537)
1. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
[TBL] [Abstract][Full Text] [Related]
2. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
6. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
Lukashova-v Zangen I; Kneitz S; Monoranu CM; Rutkowski S; Hinkes B; Vince GH; Huang B; Roggendorf W
Acta Neuropathol; 2007 Mar; 113(3):325-37. PubMed ID: 17265049
[TBL] [Abstract][Full Text] [Related]
7. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.
Armstrong TS; Vera-Bolanos E; Bekele BN; Aldape K; Gilbert MR
Neuro Oncol; 2010 Aug; 12(8):862-70. PubMed ID: 20511182
[TBL] [Abstract][Full Text] [Related]
8. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
9. [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors].
Figarella-Branger D; Metellus P; Barrié M; Maues de Paula A; Fernandez C; Polivka M; Vital A; Labrousse F; Vignaud JM; Laquerrière A; Rousselet MC; Lacroix C; Saikali S; Chapon F; Gontier MF; Chrétien F; Babin P; Rigau V; Vandenbos F; Peoc'h M; Kujas M; Chinot O; Gouvernet J; Giorgi R; Guyotat J; Jouvet A
Neurochirurgie; 2007 Jun; 53(2-3 Pt 1):76-84. PubMed ID: 17445840
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
11. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
12. Expression of claudins relates to tumour aggressivity, location and recurrence in ependymomas.
Nordfors K; Haapasalo J; Sallinen PK; Haapasalo H; Soini Y
Histol Histopathol; 2013 Sep; 28(9):1137-46. PubMed ID: 23423606
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
[TBL] [Abstract][Full Text] [Related]
14. Nestin expression identifies ependymoma patients with poor outcome.
Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
16. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
17. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
18. A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas.
Sharma MC; Ghara N; Jain D; Sarkar C; Singh M; Mehta VS
Neuropathology; 2009 Apr; 29(2):148-55. PubMed ID: 18721229
[TBL] [Abstract][Full Text] [Related]
19. Disseminated ependymomas of the central nervous system.
Rezai AR; Woo HH; Lee M; Cohen H; Zagzag D; Epstein FJ
J Neurosurg; 1996 Oct; 85(4):618-24. PubMed ID: 8814165
[TBL] [Abstract][Full Text] [Related]
20. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
